1H-吡咯并[2,3-c]吡啶-2-甲醛 | 867034-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 1H-吡咯并[2,3-c]吡啶-2-甲醛
• 中文别名: 6-氮杂吲哚-2-甲醛
• 英文名称: 1H-pyrrolo[2,3-c]pyridine-2-carbaldehyde
• CAS: 867034-96-6
• 化学式: C₈H₆N₂O
• mdl: MFCD06738309
• 分子量: 146.148
• InChiKey: NIGOYOCBOWKYSW-UHFFFAOYSA-N

物化性质

• 沸点：
  383.2±22.0 °C(Predicted)
• 密度：
  1.368±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1H-吡咯并[2,3-c]吡啶-2-甲醛 在 manganese(IV) oxide 作用下， 以 四氢呋喃 为溶剂， 反应 2.75h， 生成 1-(1H-吡咯并[2,3-c]吡啶-2-基)乙酮
  参考文献：
  名称：

  [EN] 6-AZAINDOLE COMPOUND
  [FR] COMPOSE DE 6-AZAINDOLE

  摘要：

  公开号：

  WO2005097129A3

文献信息

• [EN] FACTOR XIIA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR XIIA
  申请人：UNIV LEEDS INNOVATIONS LTD

  公开号：WO2019186164A1

  公开（公告）日：2019-10-03

  This invention relates to compoundsof formula (I)and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

  本发明涉及公式(I)的化合物以及使用这些化合物进行治疗的方法。该发明还涉及用于生产该发明化合物的过程和方法。该发明化合物是凝血因子XII（例如凝血因子XIIa）的调节剂。具体来说，这些化合物是凝血因子XIIa的抑制剂，可能作为抗凝血剂有用。
• [EN] PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINES KINASES
  申请人：LYTIX BIOPHARMA AS

  公开号：WO2014198844A1

  公开（公告）日：2014-12-18

  The present invention provides a compound incorporating a group of formula (I) wherein: 1 of X, Y and Z is nitrogen and the other 2 are carbon; V is sulpur or carbon; R3 is oxygen or fluorine; R4 is an optionally present C1-3 alkyl group optionally substituted by fluorine; R5 is an optionally present cyclic group with 5-7 heavy atoms in the ring which may be carbocyclic or heterocyclic and aromatic or aliphatic and is optionally substituted, e.g. by a halogen, C1-2 alkyl or fluoroalkyl, OH, OR6, cyano, COOR6, CONHR6, sulfonamide or NHR6, in which R6 is a C1-2 alkyl or fluoroalkyl; at least one of R4 and R5 is present and R4 and R5 may both be present; m and n are each 1 or 2 depending on the identity of V and R3; when n=2 each R3 may be the same or different but are preferably the same, when m=2, each R4 and each R5 may be the same or different but are preferably the same; and W represents hydrogen, carbon, nitrogen, oxygen or sulphur; or incorporating a salt, hydrate or solvate of a group of formula (I); as well as therapeutic uses of these compounds, in particular as inhibitors of protein kinase activity and in the treatment of inflammation, inflammatory conditions and cancer.

  本发明提供了一种化合物，该化合物包含一个公式（I）的基团，其中：X、Y和Z中的1个是氮，另外2个是碳；V是硫或碳；R3是氧或氟；R4是一种可选的C1-3烷基，可选择地被氟取代；R5是一个可选的含有5-7个重原子的环状基团，该环可以是碳环或杂环，芳香或脂肪，并且可选择地被取代，例如通过卤素、C1-2烷基或氟烷基、羟基、OR6、氰基、COOR6、CONHR6、磺酰胺基或NHR6，其中R6是C1-2烷基或氟烷基；R4和R5中至少有一个存在，R4和R5可能同时存在；m和n分别为1或2，取决于V和R3的身份；当n=2时，每个R3可以相同也可以不同，但最好是相同的；当m=2时，每个R4和每个R5可以相同也可以不同，但最好是相同的；W代表氢、碳、氮、氧或硫；或者包含公式（I）基团的盐、水合物或溶剂化合物；以及这些化合物的治疗用途，特别是作为蛋白激酶活性抑制剂和治疗炎症、炎症性疾病和癌症的用途。
• 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS
  申请人：Galxo Group Limited

  公开号：US20150175600A1

  公开（公告）日：2015-06-25

  Compounds of formula (I): wherein; R 1 is hydrogen or C 1-6 alkyl; R 2 is hydrogen, C 1-6 alkyl, perhalomethylC 0-5 alkyl-O—, or C 1-6 alkoxy; R 3 is hydrogen, C 1-6 alkyl, or C 1-6 alkoxyC 1-6 alkyl; R 4 is hydrogen, C 1-6 alkyl, perhalomethylC 1-6 alkyl; or unsubstituted C 3-6 cycloalkylC 1-6 alkyl; A is C—R 5 or N; B is C—R 6 or N; D is C—R 7 or N; with the proviso that at least one of A, B, and D, is N; R 5 is hydrogen or C 1-6 alkyl; R 6 is hydrogen or C 1-6 alkyl; R 7 is hydrogen, C 1-6 alkyl, C 1-6 alkoxy, or hydroxy; R 8 is hydrogen or C 1-6 alkyl, with the proviso that one of R 4 and R 8 is hydrogen; R 9 is hydrogen or hydroxy; R 10 is hydrogen or C 1-6 alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

  式（I）的化合物：其中；R1为氢或C1-6烷基；R2为氢、C1-6烷基、全氟甲基C0-5烷基-O—、或C1-6烷氧基；R3为氢、C1-6烷基，或C1-6烷氧基C1-6烷基；R4为氢、C1-6烷基、全氟甲基C1-6烷基；或未取代的C3-6环烷基C1-6烷基；A为C—R5或N；B为C—R6或N；D为C—R7或N；但要求A、B、和D中至少有一个为N；R5为氢或C1-6烷基；R6为氢或C1-6烷基；R7为氢、C1-6烷基、C1-6烷氧基，或羟基；R8为氢或C1-6烷基，但要求R4和R8中的一个为氢；R9为氢或羟基；R10为氢或C1-6烷基；其盐为PAD4抑制剂，可能在治疗各种疾病中有用，例如类风湿性关节炎、血管炎、系统性红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、皮肤红斑性狼疮和牛皮癣。
• Diazaindenes (azaindoles). Part III. Reactions of Vilsmeier reagents leading to 3-formyl-1,6-diazaindene and -1,4-diazabenz[f]indene
  作者：B. A. J. Clark、J. Parrick、P. J. West、A. H. Kelly

  DOI：10.1039/j39700000498

  日期：——

  The action of the two Vilsmeier reagents from dimethylformamide and phosphoryl chloride or thionyl chloride on 2-amino-3-picoline, 3-amino-4-picoline, and 4-amino-3-picoline is reported. The first reagent with 3-amino-4-picoline gave 3-formyl-1,6-diazaindene (pyrrolo[2,3-c]pyridine-3-carbaldehyde) and NN-dimethyl-N′-(4-methyl-3-pyridyl)formamidine, and with 3-amino-2-methylquinoline yielded 3-formyl-1

  报道了来自二甲基甲酰胺和磷酰氯或亚硫酰氯的两种Vilsmeier试剂对2-氨基-3-甲基吡啶，3-氨基-4-甲基吡啶和4-氨基-3-甲基吡啶的作用。与3-氨基-4-甲基吡啶的第一试剂，得到3-甲酰基-1,6- diazaindene（吡咯并[2,3- c ^ ]吡啶-3-甲醛）和NN二甲基Ñ ' - （4-甲基-3- -吡啶基）甲idine，并与3-氨基-2-甲基喹啉生成3-甲酰基-1,4-二氮杂苯并[ f ]-茚（吡咯并[3,2 - b ]喹啉-3-甲醛）。研究了醛的一些改性。3-（NN二甲基氨基甲基）-1,6-二diazaindene制备。
• [EN] SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS<br/>[FR] EXO-MÉTHYLÈNE-OXINDOLES SUBSTITUÉS QUI SONT DES INHIBITEURS DE HPK1/MAP4K1
  申请人：GILEAD SCIENCES INC

  公开号：WO2020237025A1

  公开（公告）日：2020-11-26

  The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

  本公开涉及某些烯酮吲哚化合物，包括它们的制药组合物。还公开了制备和使用所述化合物和制药组合物的方法。本文所披露的化合物和组合物可用于治疗或预防可以通过造血祖细胞激酶1（HPK1）抑制剂进行调节的疾病、紊乱或感染，例如乙型肝炎病毒（HBV）、人类免疫缺陷病毒（HIV）、癌症和/或过度增殖性疾病。